Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Active parathyroid glands among renal dialysis patients contribute to calcified and hardened
blood vessels. Such damage to the blood vessels, in turn, takes a significant toll in terms
of cardiovascular disease. Calcimimetics has been suggested to lower the risk of vascular
calcification. Role of cinacalcet was demonstrated in animal model but human data are
lacking. The investigators designed an open label pilot study to evaluate the effect of
cinacalcet in 20 peritoneal dialysis patients with inadequately controlled secondary
hyperparathyroidism despite standard treatment. The primary outcome is the aortic pulse wave
velocity at 26 and 52 months after cinacalcet treatment.